StockMirror — Stock Screener

LAURUSLABS Q2 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

Laurus Labs reported a landmark Q2 FY27 with record revenue of INR 2,206 crores and PAT of INR 441 crores, driven by an exceptional 86% YoY growth in its CDMO business. EBITDA margins expanded to 34.5% on improved operational leverage and a favorable product mix. Management is executing a significant transformation strategy, investing heavily in new capabilities and capacities for complex modalities like peptides and oligonucleotides, which are expected to be key growth drivers in the future. While they do not provide specific revenue guidance, they reiterate confidence in sustaining margins above 60% gross and 30% EBITDA.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

The company is pursuing a balanced approach. While it is making significant growth-focused capex investments (~INR 1,500 crores annually) in new capacities and technologies, it is also maintaining a strong focus on profitability, re-iterating its guidance of >60% gross margin and >30% EBITDA margin.

About Laurus Labs Limited

Laurus Labs Limited (LAURUSLABS) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More